0
Clinical Investigations: PULMONARY FIBROSIS |

Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis*: A Metaanalysis

Ednan K. Bajwa, MD; Najib T. Ayas, MD MPH; Michael Schulzer, MD, PhD; Edwin Mak, BSC; Jay H. Ryu, MD; Atul Malhotra, MD, FCCP
Author and Funding Information

*From the Division of Pulmonary and Critical Care Medicine (Drs. Bajwa and Malhotra), Brigham and Women’s Hospital, Boston MA; the Department of Medicine (Drs. Ayas and Schulzer) and the Pacific Parkinson’s Research Centre (Mr. Mak), University of British Columbia, Vancouver, BC, Canada; and the Division of Pulmonary and Critical Care Medicine (Dr. Ryu), Mayo Clinic, Rochester, MN.

Correspondence to: Atul Malhotra, MD, FCCP, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115; e-mail: amalhotra1@partners.org



Chest. 2005;128(1):203-206. doi:10.1378/chest.128.1.203
Text Size: A A A
Published online

Context: Despite the investigation of multiple therapeutic options, idiopathic pulmonary fibrosis (IPF) remains a devastating, progressively fatal disease. Much interest has focused on the use of interferon (IFN)-γ1b therapy, but the efficacy of this treatment has not been proven.

Objective: To determine whether IFN treatment reduces mortality in patients with IPF.

Design: A metaanalysis of randomized controlled trials evaluating the use of IFN-γ1b as treatment for IPF.

Main outcome measure: Mortality in patients treated with IFN-γ1b was compared to mortality in patients treated with control therapies.

Results: A total of three studies involving 390 patients was included in the analysis. IFN-γ1b therapy was associated with reduced mortality (hazard ratio [HR], 0.418; 95% confidence interval [CI], 0.253 to 0.690; p = 0.0003). A comparison of mortality at different time points revealed that IFN-γ1b therapy was associated with significantly reduced mortality at 1 year (0.0861; 95% CI, 0.0244 to 0.1478; p = 0.0063), 18 months (0.1682; 95% CI, 0.1065 to 0.2299; p < 0.0001), 650 days (0.1939; 95% CI, 0.1386 to 0.2492; p < 0.0001), and 2 years (0.2652; 95% CI, 0.1652 to 0.3652; p < 0.0001).

Conclusion: When the results of multiple studies are combined in a metaanalysis, IFN-γ1b therapy is associated with reduced mortality.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543